Esperion Therapeutics (ESPR) Cash from Investing Activities (2012 - 2026)

Esperion Therapeutics' Cash from Investing Activities history runs 14 years deep, the most recent figure standing at -$189000.0 for Q1 2026.

• Quarterly Cash from Investing Activities changed N/A year-over-year to -$189000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$189000.0 (up 22.54% YoY) and the FY2024 annual result came in at -$317000.0, down 100.75% from the prior year.
• Cash from Investing Activities was -$189000.0 for Q1 2026 at Esperion Therapeutics, down from -$167000.0 in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $33.0 million in Q3 2022 and bottomed at -$18.1 million in Q1 2022.
• A 4-year average of $5.0 million and a median of -$75000.0 in 2024 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 250.0% — and 2024, when it slumped 100.44%.
• Esperion Therapeutics' Cash from Investing Activities stood at -$11.8 million in 2022, then surged by 248.38% to $17.5 million in 2023, then tumbled by 100.95% to -$167000.0 in 2024, then slipped by 13.17% to -$189000.0 in 2026.
• Business Quant data shows ESPR's Cash from Investing Activities at -$189000.0 in Q1 2026, -$167000.0 in Q3 2024, and -$77000.0 in Q2 2024.